AZA Combined With RCHOP in P53-mutated DLBCL.
To evaluate the efficacy and adverse effects of Azacitidine in combination with R-CHOP (ARCHOP) for the treatment of TP53-mutated previously untreated Diffuse large B-cell lymphoma
DLBCL - Diffuse Large B Cell Lymphoma|TP53
DRUG: Azacitidine in combination with R-CHOP
Complete remission rate (CR), CR is evaluated according to the Lugano criteria for lymphoma response., Up to 36 months
Partial remission rate (PR), PR is evaluated according to the Lugano criteria for lymphoma response., Up to 36 months|Overall response rate (ORR), Percentage of participants with best overall response of partial response (PR) and complete response (CR), using the Lugano criteria., Up to 36 months|Progression Free Survival (PFS), The Kaplan-Meier method will be used to estimate the rate of PFS. PFS was defined as the time from the date of treatment initiation until the date of the first documented day of disease progression or relapse, using 2014 Lugano criteria, or death from any cause, whichever occurred first., Up to 36 months
This is a Phase 2, open-label clinical trial study that aims to evaluate the efficacy (eg. Complete response, Overall Survival, Progression Free Survival) and adverse effects of Azacitidine in combination with R-CHOP (ARCHOP) for the treatment of TP53-mutated previously untreated Diffuse large B-cell lymphoma